Merck & Co.: mRNA success with Moderna could give Keytruda new momentum
Reading Time: 3 minutes
Moderna and Merck impress with phase 3 study data on the combination of the mRNA cancer vaccine Intismeran and the immunotherapy Keytruda. The second quarter was convincing with a revenue increase of 5%, primarily driven by the cancer drug Keytruda and new product launches. Due to the acquisition of Terns Pharmaceuticals for USD 5.7 billion, completed in May 2026, the earnings forecast for fiscal year 2026 had to be lowered. While Moderna (MRNA) was listed pre-market on August 19 with an increase of over 100%, Merck & Co. (MRK)...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
